CAROL VANDERZWAAG: Open Payments
NPI 1215161492 · RALEIGH, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$446 in 20 payments from 9 companies in 2025. Trend: 2023 $197 · 2024 $200 · 2025 $446
Food & beverage: $446
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 5 | $110 |
| Alkermes, Inc. | 4 | $95 |
| Otsuka America Pharmaceutical, Inc. | 3 | $80 |
| Janssen Pharmaceuticals, Inc | 3 | $49 |
| Neurocrine BioSciences, Inc. | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| Luye Pharma (USA) Ltd. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
Products named: COBENFY, ARISTADA, ABILIFY ASIMTUFII, INVEGA SUSTENNA, INGREZZA, HETLIOZ, ERZOFRI EXTENDED-RELEASE, ABILIFY MAINTENA.
Industry payments across NC — which companies pay providers there.
